[{"id":"bce05c4f-6c6a-4884-8079-4fd16c00542d","acronym":"KISIMA-02","url":"https://clinicaltrials.gov/study/NCT05846516","created_at":"2023-05-06T14:04:12.085Z","updated_at":"2024-07-02T16:34:59.526Z","phase":"Phase 1","brief_title":"A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)","source_id_and_acronym":"NCT05846516 - KISIMA-02","lead_sponsor":"Amal Therapeutics","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-06-03"}]